During the past decade, Peter MacCallum Cancer Centre conducted 290 clinical trials. In the 10-year time frame, 290 clinical trials started and 65 clinical trials were completed, i.e. on average, 22.4% percent of trials that started reached the finish line to date. In the past 5 years, 144 clinical trials started and 46 clinical trials were completed. i.e. 31.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Peter MacCallum Cancer Centre" #1 sponsor was "Peter MacCallum Cancer Centre, Australia" with 58 trials, followed by "Hoffmann-La Roche" with 37 trials sponsored, "Trans Tasman Radiation Oncology Group" with 28 trials sponsored, "Pfizer" with 23 trials sponsored and "BeiGene" with 23 trials sponsored. Other sponsors include 252 different institutions and companies that sponsored additional 136 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Peter MacCallum Cancer Centre" #1 collaborator was "Peter MacCallum Cancer Centre, Australia" with 12 trials as a collaborator, "Bristol-Myers Squibb" with 11 trials as a collaborator, "National Cancer Institute (NCI)" with 11 trials as a collaborator, "Merck Sharp & Dohme LLC" with 10 trials as a collaborator and "Trans Tasman Radiation Oncology Group" with 10 trials as a collaborator. Other collaborators include 307 different institutions and companies that were collaborators in the rest 193 trials.

According to Clinical.Site data, the most researched conditions in "Peter MacCallum Cancer Centre" are "Breast Cancer" (24 trials), "Prostate Cancer" (22 trials), "Multiple Myeloma" (17 trials), "Melanoma" (13 trials) and "Ovarian Cancer" (10 trials). Many other conditions were trialed in "Peter MacCallum Cancer Centre" in a lesser frequency.

Most popular intervention types in "Peter MacCallum Cancer Centre" are "Drug" (348 trials), "Radiation" (65 trials), "Biological" (37 trials), "Other" (28 trials) and "Procedure" (22 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (28 trials), "Atezolizumab" (24 trials), "Pembrolizumab" (20 trials), "Carboplatin" (13 trials) and "Cisplatin" (13 trials). Other intervention names were less common.

The vast majority of trials in "Peter MacCallum Cancer Centre" are 340 trials for "All" genders, 41 trials for "Male" genders and 38 trials for "Female" genders.

Currently, there are 216 active trials in "Peter MacCallum Cancer Centre". 2 are not yet recruiting, 114 are recruiting, 97 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 156 completed trials in Peter MacCallum Cancer Centre, undefined suspended trials, and 19 terminated clinical trials to date.

Out of the total trials that were conducted in Peter MacCallum Cancer Centre, 138 "Phase 1" clinical trials were conducted, 162 "Phase 2" clinical trials and 134 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 20 trials that are defined as “Not Applicable".

Peter MacCallum Cancer Centre has several departments that took part in Clinical trials: "Peter MacCallum Cancer Centre; Medical Oncology" - 26 trials, "Peter MacCallum Cancer Centre; Department of Haematology" - 6 trials, "Peter Maccallum Cancer Centre" - 4 trials, "Peter Maccallum Cancer Institute; Clinical Trial Unit" - 3 trials, "Monash Cancer Centre" - 6 trials, "Peter MacCallum Cancer Centre Pharmacy" - 2 trials, "Peter MacCallum Cancer Centre - Box Hill" - 2 trials